Recently, in an exclusive document provided to The Hill, Republican Congressman Rob Wittman and Democratic Congressman Raja Krishnamoorthi publicly released a letter addressed to Robert Califf, the Commissioner of the Food and Drug Administration (FDA), regarding their unanswered inquiries submitted to the agency in November.
They wrote, "The recent federal joint operation in December 2023 seized over 1.4 million illicit e-cigarettes, and we commend this effort. However, there is still more work to be done. Illegally manufactured e-cigarette products from China currently account for over half of all e-cigarette products sold in the United States, significantly increasing the prevalence of underage e-cigarette use.
Legislators have taken note of the fact that FDA data reveals that more than one in every four teenagers admits to using e-cigarettes on a daily basis, with a majority expressing a preference for flavored e-cigarettes.
In the letter, they specifically mentioned the ELFBAR brand, with 56% of users stating that they obtained this brand through "illegal imports" from China. This product line stands out with brightly colored e-cigarettes, available in various fruity flavors.
Critics widely believe that these types of products are specifically designed to appeal to children and teenagers. Despite the ban imposed by the Food and Drug Administration on most fruit and mint flavored e-cigarettes, these products continue to flood into the United States and remain available for purchase.
The lawmakers questioned the Food and Drug Administration (FDA) about their plans to prevent the influx of e-cigarettes from China and whether they intended to pursue legal action against manufacturers. They also inquired why the FDA has not issued regulations requiring foreign manufacturers to register, despite the Tobacco Control Act allowing for such measures.
The FDA, which had previously stated that it would complete the review of applications by the end of December 2023, has missed the final deadline. Representatives Whitman and Krishnamoorthi are pressing the FDA for information on the timeline for completing the review and urging the agency to address the issue of delays.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
